Theravance Biopharma Announces New Employment Inducement

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Theravance Biopharma Announces New Employment Inducement Awards

DUBLIN, IRELAND--(Marketwired - Dec 2, 2015) -   Theravance Biopharma, Inc. ( NASDAQ : TBPH ) ("Theravance Biopharma" or the "Company") announced today that stock options to purchase an aggregate of 23,000 of the Company's ordinary shares were granted to six new non-executive officer employees on December 1, 2015. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4) under the Theravance Biopharma, Inc. 2014 New Employee Equity Incentive Plan (the "Inducement Plan"), which the Board of Directors of Theravance Biopharma adopted in October 2014 to facilitate the granting of equity awards to new employees. Each option has an exercise price per share equal to $19.22, which was the closing price of one Theravance Biopharma ordinary share on the Nasdaq Global Market on the date of grant. The options vest over four years, with 25% of the option shares vesting on the first anniversary of the date of grant and the remaining 75% of the option shares vesting in monthly installments over the three years thereafter. The options have a ten year term, and are subject to the terms and conditions of the Inducement Plan and applicable stock option agreement.

About Theravance Biopharma

The mission of Theravance Biopharma ( NASDAQ : TBPH ) is to create value from a unique and diverse set of assets: an approved product; a development pipeline of late-stage assets; and a productive research platform designed for long-term growth.

Our pipeline of internally discovered product candidates includes potential best-in-class opportunities in underserved markets in the acute care setting, representing multiple opportunities for value creation. VIBATIV ® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revenfenacin (TD-4208) is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily, oral treatment for opioid-induced constipation (OIC). Our earlier-stage clinical assets represent novel approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease. In addition, we have an economic interest in future payments that may be made by GlaxoSmithKline plc pursuant to its agreements with Theravance, Inc. relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol (the "Closed Triple").

With our successful drug discovery and development track record, commercial infrastructure, experienced management team and efficient corporate structure, we believe that we are well positioned to create value for our shareholders and make a difference in the lives of patients.

For more information, please visit www.theravance.com .

THERAVANCE ® , the Cross/Star logo, MEDICINES THAT MAKE A DIFFERENCE ® and VIBATIV ® are registered trademarks of the Theravance Biopharma group of companies.

Contact Information: Renee Gala Chief Financial Officer 650-808-4045 investor.relations@theravance.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Democratic Congress: Tax, Tariff, Regulation Shifts

Updated Category News Views 76

Shifting Legislative Sands for Business Giddy up, folks! The political tectonic plates just shifted with Democrats grabbing the reins of Congress. For businesses trying to keep their heads above water or score a victory lap, this change could mean adjusting to new winds blowing from Capitol Hill. What could this Democratic majority spell out for taxes, tariffs, and...

Continue Reading
Tata Power Faces Enforcement Order for $650M Debt

Updated Category News Views 148

Tata's Troubles Escalate Grab a cup of coffee, folks, because this is one rollercoaster of a story that every investor needs to have on their radar. We're talking about Singapore courts coming down on Tata Power like a freight train, with enforcement orders that feel like a page out of a high-stakes drama. The Gavel Drops: What's Happening? The court in Singapore has...

Continue Reading
TEN Holdings' Q3: Cost Cuts Fuel Revenue Ambitions

Updated Category News Views 80

TEN Holdings Eyes the Future While Cleaning House If there’s one thing that catches the eye about TEN Holdings' Q3 2026 results, it’s the laser-focused cleanup of their balance sheet. They’ve slashed liabilities by 74%, up from $7.7 million at the arse end of last year to just over $2 million now. They did that by making some hard moves, hacking away at operating...

Continue Reading
Tenax Sued: Investors Face Class Action Over TNX-103

Updated Category News Views 44

What Tenax Investors Need to Know Alright, folks, time to pull up a chair and pay attention to what's brewing with Tenax Therapeutics—yeah, we're talking NASDAQ: TENX. The company's head is spinning as it's caught up in a securities class action lawsuit. What's the fuss? The fine print here accuses Tenax of misleading investors about the effectiveness of their product,...

Continue Reading
Elanco Surges with Solid Q3, Raises 2026 Forecast

Updated Category News Views 71

Strong Q3 Performance Ignites Elanco's Growth Now here's a headline: Elanco's numbers are charging like a bull on steroids. Revenue surged 11% year-over-year to hit a cool $1.265 billion, showing off a 9% organic constant currency growth. And why should we, the investors, care? Because they've adjusted their EBITDA margin upwards to 19.5%, an impressive 2% boost from the...

Continue Reading
Habitat for Humanity AZ's Unique Gala: An Overview

Updated Category News Views 25

Mark Your Calendars: A Night to Celebrate Listen up, Central Arizona, because I'm giving you the lowdown on Habitat for Humanity Central Arizona's big night out. "Blueprints & Blue Jeans" - it's the gala that's ditching the formalities for some good old-fashioned community fun, but with a seriously important mission at its heart. Mark your calendars for Friday, March 5,...

Continue Reading
ACR Poker's $20M OSS Leads High-Stakes Weekend

Updated Category News Views 91

Sunday Showdown at ACR: A Massive Poker Feast Kicking off the action on November 8, ACR Poker brings its Online Super Series (OSS) into the spotlight, and listen up—there's a cool $20 million spread on the table through November 24. What's got people really tuned in, though, is the mix of big stakes, high tension events, and a shot at paradise over in the Bahamas....

Continue Reading
Kuaishou Prepares for Q3 Financial Reveals—November 19

Updated Category News Views 120

We're watching the countdown to November 19, 2026, when Kuaishou Technology plans to spill the beans on its third-quarter earnings. Now, the clock's ticking not just in Beijing but across the financial landscape, as investors everywhere hold their breaths, hoping for some juicy financial insights from this colossal social platform. It's a heavyweight showdown any stock...

Continue Reading
Andersen's Window Revamp: Addressing Demand Surge

Updated Category News Views 75

Portfolio Boost: Adapting to Market Needs If you're sniffing around the windows business, there's a fresh breeze of innovation blowing from Andersen. They're not just sitting around drumming their fingers—they're rolling up their sleeves and fine-tuning their offerings. With half of homeowners swinging a hammer on renovations last year, the company sees an opportunity...

Continue Reading
McKinley Irvin Earns Top 2027 Rankings in Family Law

Updated Category News Views 60

A Legal Eagle Soars High in 2027 Oh, the legal world can be as cutthroat as the stock market some days, especially when you're gunning for those top-tier rankings. This year, McKinley Irvin has managed to ruffle a few feathers in the Pacific Northwest, claiming top honors in the 2027 Best Law Firms rankings. And let me tell you, this wasn’t just handed to them on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Outcrop Silver & Gold Targets Growth with New Offering

Updated Category News Views 216

Outcrop Silver & Gold Corporation Pursues $20 Million Offering Outcrop Silver & Gold Corporation (TSXV: OCG) has embarked on an ambitious journey to elevate its exploration activities through a substantial public offering. The company has partnered with BMO Capital Markets and Research Capital Corporation to facilitate this strategic move, seeking to raise up to $20...

Continue Reading
Industrial Granulated Sugar Market Forecast Exceeds $50 Billion

Updated Category News Views 126

Overview of the Industrial Granulated Sugar Market The industrial granulated sugar market is on a remarkable growth trajectory from 2024 to 2031, primarily fueled by the increasing demand in the food and beverage sectors. As urban lifestyles evolve, ready-to-eat and convenience foods are gaining traction, leading to heightened reliance on granulated sugar as a fundamental...

Continue Reading
GreenPower Motor Company Closes Successful Public Offering

Updated Category News Views 124

GreenPower Motor Company Closes Successful Public Offering GreenPower Motor Company Inc. (NASDAQ: GP, TSXV: GPV), a prominent player in the all-electric vehicle market, has announced the successful closure of its public offering. This significant event has raised gross proceeds of U.S. $3 million by selling 3,000,000 common shares at a public offering price of $1.00 per...

Continue Reading
B. Riley Financial's Strategic Move Enhances Growth Prospects

Updated Category News Views 105

B. Riley Financial's Strategic Move Enhances Growth Prospects B. Riley Financial, Inc. (NASDAQ: RILY) is making headlines as its stock price sees an upward trend. This increase follows the exciting news that the company has reached an agreement to sell its appraisal and valuations division, Great American, to Oaktree Capital Management for approximately $386 million....

Continue Reading
Omdia Study Shows Major Returns on Video Analytics Investment

Updated Category News Views 75

Understanding the Impact of Video Analytics Investments Recent research has shed light on the monetary benefits of video analytics technology, revealing remarkable insights from a study led by Omdia. BriefCam®, a pioneer in AI-driven video analytics solutions, commissioned this independent analysis to understand the return on investment (ROI) related to video analytics...

Continue Reading